Dr. Reddy's Laboratories Limited (RDY) Income Statement

NYSE: RDYRevenue, profits, margins and EPS over 10 years.

RDY FY2026 at a glance

Fiscal year ended March 31, 2026 · Indian rupees
Revenue+8.6%
₹353.47B
FY2026 · hover or tap a bar for each year
FY2017: ₹140.81B (−9.0%)FY2018: ₹142.03B (+0.9%)FY2019: ₹153.85B (+8.3%)FY2020: ₹174.60B (+13.5%)FY2021: ₹2.56B (−98.5%)FY2022: ₹214.39B (+8,288.8%)FY2023: ₹245.88B (+14.7%)FY2024: ₹279.16B (+13.5%)FY2025: ₹325.54B (+16.6%)FY2026: ₹353.47B (+8.6%)
FY2017FY2026
Gross profit−2.1%
₹186.52B
FY2026 · hover or tap a bar for each year
FY2017: ₹78.36B (−15.1%)FY2018: ₹76.30B (−2.6%)FY2019: ₹83.43B (+9.3%)FY2020: ₹94.01B (+12.7%)FY2021: ₹1.30B (−98.6%)FY2022: ₹113.84B (+8,671.8%)FY2023: ₹139.34B (+22.4%)FY2024: ₹163.61B (+17.4%)FY2025: ₹190.43B (+16.4%)FY2026: ₹186.52B (−2.1%)
FY2017FY2026
Operating income−32.0%
₹48.87B
FY2026 · hover or tap a bar for each year
FY2017: ₹13.50B (−54.4%)FY2018: ₹11.92B (−11.7%)FY2019: ₹20.89B (+75.3%)FY2020: ₹15.99B (−23.4%)FY2021: ₹431.4M (−97.3%)FY2022: ₹29.48B (+6,732.0%)FY2023: ₹57.14B (+93.9%)FY2024: ₹67.73B (+18.5%)FY2025: ₹71.84B (+6.1%)FY2026: ₹48.87B (−32.0%)
FY2017FY2026
Net income−20.3%
₹45.09B
FY2026 · hover or tap a bar for each year
FY2017: ₹12.04B (−39.8%)FY2018: ₹9.81B (−18.5%)FY2019: ₹18.80B (+91.7%)FY2020: ₹19.50B (+3.7%)FY2021: ₹232.2M (−98.8%)FY2022: ₹23.57B (+10,049.5%)FY2023: ₹45.07B (+91.2%)FY2024: ₹55.68B (+23.6%)FY2025: ₹56.54B (+1.5%)FY2026: ₹45.09B (−20.3%)
FY2017FY2026
Net profit margin−4.6 pts
12.8%
FY2026 · hover or tap a point for each year
FY2017: 8.5% (−4.4 pts)FY2018: 6.9% (−1.6 pts)FY2019: 12.2% (+5.3 pts)FY2020: 11.2% (−1.0 pts)FY2021: 9.1% (−2.1 pts)FY2022: 11.0% (+1.9 pts)FY2023: 18.3% (+7.3 pts)FY2024: 19.9% (+1.6 pts)FY2025: 17.4% (−2.6 pts)FY2026: 12.8% (−4.6 pts)
FY2017FY2026

RDY revenue and net income

RevenueNet incomeNet margin (right axis)

Where RDY's revenue goes

FY2026
Revenue
₹353.47B100.0%
Cost of revenue
−₹166.95B−47.2%
Gross profit
₹186.52B52.8%
Research & development
−₹25.31B−7.2%
Sales, general & admin
−₹59.91B−16.9%
Other operating expenses
−₹52.43B−14.8%
Operating income
₹48.87B13.8%
Interest & other income
₹8.81B2.5%
Income taxes
−₹13.00B−3.7%
Net income
₹45.09B12.8%

Each bar shows an amount and its share of revenue. RDY kept 12.8% of revenue as net income.

RDY profit margins

GrossOperatingNet

RDY growth rates

to FY2026
1 year3 years5 years10 years
Revenue+8.6%+12.9%+168.0%+8.6%
Gross profit−2.1%+10.2%+170.1%+7.3%
Operating income−32.0%−5.1%+157.5%+5.1%
Net income−20.3%+0.0%+186.8%+8.5%

1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.

RDY income statement in Indian rupees

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue₹353.47B₹325.54B₹279.16B₹245.88B₹214.39B₹2.56B₹174.60B₹153.85B₹142.03B₹140.81B
Cost of revenue₹166.95B₹135.11B₹115.56B₹106.54B₹100.55B₹1.26B₹80.59B₹70.42B₹65.72B₹62.45B
Gross profit₹186.52B₹190.43B₹163.61B₹139.34B₹113.84B₹1.30B₹94.01B₹83.43B₹76.30B₹78.36B
Research & development₹25.31B₹27.38B₹22.87B₹19.38B₹17.48B₹208.4M₹15.41B₹15.61B₹18.27B₹19.55B
Sales, general & admin₹59.91B₹93.87B₹77.20B₹46.47B₹62.08B₹54.56B₹50.13B₹707.0M₹720.0M₹715.0M
Total operating expenses₹137.65B₹118.58B₹95.88B₹82.20B₹84.36B₹866.4M₹78.02B₹62.54B₹64.39B₹64.86B
Operating income₹48.87B₹71.84B₹67.73B₹57.14B₹29.48B₹431.4M₹15.99B₹20.89B₹11.92B₹13.50B
Interest income₹3.73B₹2.68B₹2.28B₹1.06B₹3.08B₹1.65B₹2.03B₹1.55B₹2.42B₹1.16B
Interest expense₹3.93B₹2.83B₹1.71B₹1.43B₹958.0M₹970.0M₹13.9M₹889.0M₹788.0M₹634.0M
Income before taxes₹57.68B₹76.78B₹71.87B₹60.37B₹32.30B₹355.8M₹18.03B₹22.44B₹14.34B₹14.65B
Income taxes₹13.00B₹19.54B₹16.19B₹15.30B₹8.73B₹123.6M−₹1.47B₹3.65B₹4.54B₹2.61B
Net income₹45.09B₹56.54B₹55.68B₹45.07B₹23.57B₹232.2M₹19.50B₹18.80B₹9.81B₹12.04B
EBITDA₹83.29B₹96.67B₹88.42B₹74.43B₹45.08B₹13.16B₹41.78B₹35.52B₹23.63B₹24.77B
Gross margin52.8%58.5%58.6%56.7%53.1%50.8%53.8%54.2%53.7%55.6%
Operating margin13.8%22.1%24.3%23.2%13.7%16.9%9.2%13.6%8.4%9.6%
Net margin12.8%17.4%19.9%18.3%11.0%9.1%11.2%12.2%6.9%8.5%

Quarterly columns are labeled by the month the quarter ended. Figures in Indian rupees as reported in RDY's financial statements (latest annual report filed May 29, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.

RDY financial results

In fiscal year 2026 (ended March 31, 2026), Dr. Reddy's Laboratories reported revenue of ₹353.5 billion, up 8.6% from the year before. It had net income of ₹45.1 billion (down 20.3%), a net profit margin of 12.8%. Over five years revenue grew at an average rate of 168.0% a year. Figures are in Indian rupees, the currency of its financial statements.

See the RDY stock overview for the latest quote and news, or the RDY chart for price history and technical indicators.

RDY income statement FAQ

What is Dr. Reddy's Laboratories's annual revenue?

Dr. Reddy's Laboratories reported total revenue of ₹353.5 billion for fiscal year 2026, which ended on March 31, 2026. That was up 8.6% from ₹325.5 billion the previous year.

Is Dr. Reddy's Laboratories profitable?

Yes. Dr. Reddy's Laboratories reported net income of ₹45.1 billion in fiscal 2026, a net profit margin of 12.8%; its operating margin was 13.8%.

What is Dr. Reddy's Laboratories's gross margin?

Dr. Reddy's Laboratories's gross margin was 52.8% in fiscal 2026: for every $100 of revenue, Dr. Reddy's Laboratories kept $53 after the direct cost of its products and services.

How much does Dr. Reddy's Laboratories spend on research and development?

Dr. Reddy's Laboratories spent ₹25.3 billion on research and development in fiscal 2026, 7.2% of revenue.

How fast is Dr. Reddy's Laboratories growing?

Revenue grew 168.0% a year on average over the last five fiscal years, from ₹2.6 billion to ₹353.5 billion.

When will Dr. Reddy's Laboratories report its next earnings?

Dr. Reddy's Laboratories is expected to report results for the quarter ending September 30, 2026 on October 23, 2026 before the market opens.

When does Dr. Reddy's Laboratories's fiscal year end?

Dr. Reddy's Laboratories's fiscal year ends in March. The latest annual report covers the year ended March 31, 2026 and was filed on May 29, 2026.

Drug Manufacturers - Specialty & Generic income statements